Physician profile
Gina M Marcon
NPI 1760662811
$2,723.08
in general payments reported to CMS, 2019-2025
16 companies · $785 in 2025
The $785 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $584 · 2023: $478 · 2024: $291 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,553.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $465.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $362.82 | 2021-2024 | Austedo Xr |
| Pfizer INC. | $298.19 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $201.20 | 2025 | |
| Corcept Therapeutics | $140.53 | 2025 | Korlym |
| Abbott Laboratories | $139.89 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Si-Bone, INC. | $139.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $125.00 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $116.02 | 2023 | Dupixent |
| Shield Therapeutics INC | $115.30 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $115.29 | 2025 | |
| Phadia US INC. | $107.83 | 2024 | Immunocap |
| Novo Nordisk INC | $103.43 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $102.20 | 2023 | Relyvrio |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $99.99 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $90.45 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Marcon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.